TOP AGO TUMOR SECRETS

In summary, over the past ten years one of the most outstanding advantage is attained in HER2/neu-overexpressing MBC. Introduction of bevacizumab for a VEGF-directed specific therapy stays a concern on discussion. Many of the novel therapeutics to the breast cancer armamentarium resulted in prolongation of survival for people with MBC. At the momen